A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus

Brief summary (registry, in English)

The purpose of this study is to evaluate long-term safety and tolerability of dapirolizumab pegol treatment.

What you commit to

• Study type: Interventional · Phase 3
• Planned participants: 760
• From 27 Jul 2021 to the primary completion date, 7 Aug 2030
• 184 sites in 27 countries
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Who the study is looking for

Age in the registry: 16 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (184)

Sites in registry order. Save your city in your profile to sort them by distance.